Lots in the papers this morning about the US company, Geron, halting its stem cell study on spinal cord injury. I thought I would share this coverage from the Washington Post. Geron's decision highlights a lot of interesting issues around science funding.. ..the long-term nature of science ...the difficulties for the private sector in keeping … Continue reading Washington Post coverage of Geron halting its stem cell trial on spinal cord injury